IMV | Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting

IMV Inc.(Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that updated clinical data from phase 2 SPiReL study evaluating IMV’s T cell therapy in combination with Merck’s Keytruda in patients with relapsed / refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) […]